Search

A 23-year-old man with osteoblastic central osteosarcoma experienced lack of efficacy with various treatments, including cabozantinib, olaparib, trabectedin, docetaxel, and gemcitabine. After developing multiple new bone and lung metastases, he underwent off-label treatment with alpelisib, which also proved ineffective. Despite efforts, the patient ultimately passed away due to progressive lung failure. The case highlights the challenges of treating advanced osteosarcoma and the limitations of current therapies. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of multiple drugs in the treatment of pancreatic acinar cell carcinoma (PACC) in an elderly man. The patient initially underwent laparoscopic distal pancreatectomy but experienced a recurrence of PACC. He then received gemcitabine and paclitaxel as first-line chemotherapy, but the disease progressed. Second-line treatment with gimeracil/oteracil/tegafur was also ineffective, and radiotherapy was added. Eventually, the patient responded positively to oxaliplatin, folinic-acid, and fluorouracil, but the dose had to be reduced due to fatigue. The treatment was switched to olaparib, and one year after discontinuing olaparib, the patient was still alive. [Extracted from the article]

A retrospective cohort study involving 40 patients with isocitrate dehydrogenase mutated stage IV intrahepatic cholangiocarcinoma was conducted to assess the efficacy and side effects of various drugs. Two female patients were described who exhibited lack of efficacy during treatment with nivolumab, ipilimumab, gemcitabine, cisplatin, and off-label treatment with olaparib. Both patients developed side effects such as anaemia, thrombocytopenia, and neutropenia during olaparib treatment. The study highlights the need for further research on the use of these drugs for this type of cancer. [Extracted from the article]

This article presents three case reports of women with stage IIIC ovarian cancer who experienced lack of efficacy, drug intolerance, and grade 3 autoimmune side effects during treatment with various drugs. The first patient exhibited lack of efficacy to bevacizumab and doxorubicin-liposomal, and later developed grade 4 lipase elevation and grade 4 hepatitis during treatment with nivolumab and ipilimumab. The second patient experienced disease recurrence despite multiple lines of therapy, and eventually died due to ovarian cancer. The third patient had lack of efficacy to carboplatin, cyclophosphamide, olaparib, pembrolizumab, and niraparib, and developed grade 3 autoimmune side effects during treatment with ipilimumab and nivolumab. [Extracted from the article]

A retrospective analysis of 38 female patients with ovarian cancer who were treated with olaparib revealed that some patients developed anaemia or neutropenia. The patients, whose ages were not specified, received olaparib tablets 300mg/12 h and experienced grade 2 anaemia or neutropenia. The adverse effects were considered to be related to olaparib treatment. [Extracted from the article]

A case report published in Reactions Weekly describes a female patient who developed hyperglycemia while being treated with olaparib for ovarian cancer. The patient, whose age was not provided, initially had normal blood sugar levels but later developed hyperglycemia, which is a sign of diabetes. The report suggests that the hyperglycemia was caused by the olaparib treatment. The study involved 32 patients, but no further details about the other patients were provided. [Extracted from the article]

In a single-centre retrospective study, a female patient with ovarian cancer developed a rash while receiving treatment with olaparib. The specific details of the patient's age, dosage, duration of treatment, and outcome were not provided. However, it was noted that the rash was a secondary effect of olaparib and that the medication was subsequently discontinued. [Extracted from the article]

A 70-year-old woman experienced drug-induced liver injury while being treated with olaparib for somatic high-grade serous carcinoma of tubo-ovarian origin. She had a history of the disease and had undergone previous surgeries and chemotherapy. After starting olaparib, her liver enzymes became significantly elevated, leading to the discontinuation of the drug. She was later diagnosed with olaparib-induced liver injury and experienced a gradual improvement in liver function after stopping the medication. She was subsequently started on a different drug, niraparib, with no recurrence of liver injury. [Extracted from the article]

A 46-year-old man with metastatic adenocarcinoma of the pancreas experienced a lack of efficacy during treatment with multiple antineoplastic drugs, including gemcitabine, paclitaxel, folinic-acid, fluorouracil, oxaliplatin, and irinotecan. Despite undergoing three lines of chemotherapy, the patient's tumor progressed rapidly and his overall physical condition deteriorated. He was hospitalized and planned to receive fourth line chemotherapy with olaparib, but this treatment was never initiated. Unfortunately, the patient passed away a few weeks after being admitted to the hospital due to metastatic adenocarcinoma of the pancreas. [Extracted from the article]

A study analyzed 338 patients with ovarian cancer who were treated with bevacizumab and olaparib between January and December 2023. The study described a female patient with ovarian cancer who did not respond to the treatment, indicating a lack of efficacy. Despite receiving olaparib and bevacizumab, the patient experienced disease progression. [Extracted from the article]

A 60-year-old woman experienced anaemia and lack of efficacy during off-label treatment with olaparib for pelvic high-grade osteosarcoma. She also had an increased concentration of apixaban, a drug she was taking for deep vein thrombosis prophylaxis, due to a drug-drug interaction with olaparib. The woman received red blood cell transfusions for the anaemia and the apixaban concentration decreased when olaparib was temporarily stopped. However, when olaparib was restarted, the apixaban concentration increased again. Despite continued treatment with both drugs, the woman's disease progressed, indicating a lack of efficacy. The increased apixaban concentration was attributed to a pharmacokinetic drug-drug interaction with olaparib. [Extracted from the article]

A Phase III study was conducted on 357 patients between January 2019 and June 2020, and it reported a case of a woman with BRCA-mutated advanced ovarian cancer who developed myelodysplastic syndrome/acute myeloid leukemia while being treated with olaparib. The woman had been receiving platinum-based chemotherapy and had recently started olaparib treatment. The case was reported in France, but no further details about the patient's age, treatment duration, or outcome were provided. [Extracted from the article]

A 65-year-old woman with stage 2B papillary serous adenocarcinoma exhibited lack of efficacy during treatment with carboplatin, paclitaxel, and olaparib. She had a history of breast cancer and received various treatments, including chemotherapy and radiation, for metastatic disease. Despite receiving multiple lines of therapy, her cancer continued to progress. She later developed pancytopenia and was diagnosed with secondary acute myeloid leukemia. Treatment with azacitidine and low dose cytarabine with cladribine was initiated. [Extracted from the article]

A Phase III study was conducted on 357 patients between January 2019 and June 2020, and it reported a case of a woman with BRCA-mutated advanced ovarian cancer who developed myelodysplastic syndrome/acute myeloid leukemia while being treated with olaparib. The woman had been receiving platinum-based chemotherapy and had recently started olaparib treatment. The case was reported in France, but no further details about the patient's age, treatment duration, or outcome were provided. [Extracted from the article]

A 65-year-old woman with stage 2B papillary serous adenocarcinoma exhibited lack of efficacy during treatment with carboplatin, paclitaxel, and olaparib. She had a history of breast cancer and received various treatments, including chemotherapy and radiation, for metastatic disease. Despite receiving multiple lines of therapy, her cancer continued to progress. She later developed pancytopenia and was diagnosed with secondary acute myeloid leukemia. Treatment with azacitidine and low dose cytarabine with cladribine was initiated. [Extracted from the article]

A 77-year-old patient experienced nausea and fatigue while being treated with olaparib for recurrent epithelial ovarian cancer and end-stage renal disease. The patient had been receiving olaparib capsules for 16 months without interruption, but treatment was discontinued due to progressive disease. The nausea and fatigue were mild and subsided after a few weeks of therapy. [Extracted from the article]

A 77-year-old patient experienced nausea and fatigue while being treated with olaparib for recurrent epithelial ovarian cancer and end-stage renal disease. The patient had been receiving olaparib capsules for 16 months without interruption, but treatment was discontinued due to progressive disease. The patient's symptoms of nausea and fatigue subsided after a few weeks of therapy. [Extracted from the article]

A 61-year-old woman experienced acute kidney injury while being treated with olaparib for metastatic ovarian cancer. The patient had pre-existing conditions of non-insulin dependent type II diabetes and hypertension. Her creatinine levels increased over several months, reaching a peak of 2.0 mg/dl and an eGFR of 28 ml/min. However, subsequent tests showed that the increase in serum creatinine was non-pathologic, and the patient continued her treatment with olaparib. [Extracted from the article]

A study involving 389 women with ovarian cancer who were treated with bevacizumab, niraparib, or olaparib found that seven of them developed thrombotic microangiopathy or acute kidney injury (AKI). The cases included women ranging in age from 25 to over 80 years old. The specific dosages, routes, duration of treatment, and outcomes were not provided. The study highlights the potential risks of these medications in relation to kidney function. [Extracted from the article]

A 60-year-old woman with high-grade serous ovarian cancer experienced neutropenia while being treated with gemcitabine and camonsertib. She also showed lack of efficacy when treated with cisplatin, carboplatin, olaparib, paclitaxel, and bevacizumab. Despite undergoing various treatments, the progression of her ovarian cancer continued. Dose reductions and adjustments were made to her medications, and some improvement was observed. [Extracted from the article]

A chart review study examined the case of a female patient with relapsed ovarian cancer who developed severe folic-acid-deficiency while being treated with olaparib. The patient's outcome and specific treatment details were not provided. The study suggests a potential link between olaparib therapy and folic acid deficiency in this particular case. Further research is needed to determine the extent and significance of this association. [Extracted from the article]

In a study conducted between January 2020 and March 2023, 129 women with ovarian cancer were observed to develop vomiting during treatment with olaparib or niraparib. The specific dosages, duration of treatments, and outcomes were not provided. One patient experienced very severe vomiting with olaparib, while another patient experienced severe vomiting with niraparib. Further details about the study and the patients' ages were not mentioned. [Extracted from the article]

A 64-year-old woman with ovarian cancer developed pulmonary actinomycosis while being treated with olaparib. She also experienced a lack of efficacy when treated with azithromycin for the actinomycosis. The woman had been receiving olaparib for 5 months and had a stable condition. She was eventually diagnosed with pulmonary actinomycosis secondary to olaparib and was successfully treated with benzylpenicillin. After two weeks, her symptoms improved and she was discharged without complications. Three months later, a follow-up CT scan showed that the lesions had nearly disappeared. [Extracted from the article]

A 74-year-old woman developed interstitial lung disease (ILD) and myelosuppression while being treated with olaparib for ovarian cancer. She initially visited the emergency department due to a prolonged fever, which was initially thought to be an infection and treated with antipyretics and levofloxacin. However, her condition did not improve, and she started receiving olaparib treatment for over 13 months. Due to continuous use, olaparib caused myelosuppression and her hemoglobin levels dropped. A week before her visit, her olaparib was discontinued and she received a blood transfusion. She continued to have a fever, and her chest CT revealed ground-glass opacities in both lung fields. Based on the CT findings, hypersensitivity pneumonia (HP) caused by olaparib was considered the most likely cause of the ILD. She was treated with prednisolone and her symptoms improved. Follow-up CT scans showed the disappearance of the ground-glass opacities. She was discharged from the hospital and did not experience a recurrence of the fever. [Extracted from the article]

A 61-year-old man developed eosinophilic pneumonia while being treated with olaparib for metastatic prostate cancer. The man experienced symptoms such as low-grade fever, cough, chest tightness, and shortness of breath. After various examinations, a diagnosis of eosinophilic pneumonia was made, and it was suspected to be induced by olaparib. The man's olaparib therapy was discontinued, and he was treated with methylprednisolone and anti-infective medication, which resolved his symptoms. A follow-up chest CT scan showed improvement in lung inflammation. [Extracted from the article]

A case series involving 28 women with ovarian cancer found that one woman developed lung injury while being treated with olaparib. The woman experienced bilateral ground glass opacity and multiple micronodules on chest CT imaging. She was diagnosed with olaparib-induced lung injury and her treatment with olaparib was stopped. Fortunately, she fully recovered without needing any further treatment. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 70-year-old man developed purpuric drug eruption of the fingers and fingertips during treatment with olaparib for prostate cancer. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 48‑year‑old woman developed acute-myeloid-leukaemia during treatmeant with carboplatin, olaparib and pacitaxel for ovarian cancer [not all routes and dosages stated; time to reaction onset and outcome not stated]. [Extracted from the article]

A retrospective series of 20 patients with glioma who were treated with olaparib and temozolomide revealed various toxicities and lack of efficacy. The patients, consisting of 17 men and 3 women aged 24-75 years, experienced symptoms such as abdominal cramping, diarrhea, muscle and joint pain, constipation, fatigue, nausea, vomiting, weight loss, pneumocystis pneumonia, emesis, epistaxis, dyspepsia, insomnia, and mucositis. Some patients also had concurrent lymphopenia, leukopenia, thrombocytopenia, neutropenia, or cytopenia. Furthermore, 13 patients experienced progressive disease, indicating a lack of efficacy. As a result, the dosages of temozolomide and olaparib were reduced in some patients, and ultimately, treatment with both drugs was discontinued for all patients. [Extracted from the article]

In a retrospective case-control study, 18 patients who received olaparib for cancer treatment developed anaemia. The patients, including 2 men and 16 women, ranged in age from their early 30s to early 80s. All patients experienced grade ≥3 anaemia, with haemoglobin levels between 5-8.4 g/dL. One patient had their olaparib dose reduced, while the remaining 17 patients discontinued the medication. Some patients received red blood cell transfusions or iron supplementation. The specific routes, duration of treatment, and outcomes were not provided in the article. [Extracted from the article]

In a single-centre analysis of 14 female patients with BRCA-positive ovarian cancer, two patients experienced adverse effects while being treated with olaparib. One patient exhibited a lack of efficacy, as their disease rapidly progressed despite treatment. The other patient developed grade 3 thrombocytopenia, which led to the temporary suspension of olaparib. After correcting the thrombocytopenia, the patient was able to resume treatment with a reduced dose of olaparib. [Extracted from the article]

A case series involving 34 women with ovarian cancer (OC) found that 13 of them developed refractory cytopenia with multilineage dysplasia (RCMD), acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), or myelodysplasia with excess blasts (MDS-EB) while being treated with olaparib or niraparib. Two of these women also experienced a lack of efficacy with the treatment. The women had previously received platinum-based therapy or doxorubicin liposomal and later switched to olaparib or niraparib for metastatic OC. At the time of the myeloid malignancy diagnosis, most of the women were in remission for OC and underwent various treatments. Two women who received allogeneic hematopoietic stem cell transplant were alive but relapsed shortly after. Eleven women died due to disease progression or complications related to treatment. [Extracted from the article]

In a cohort study of 13 adult women with uterine leiomyosarcoma, three women experienced adverse effects or lack of efficacy during treatment with carboplatin, dacarbazine, ifosfamide, or off-label treatment with olaparib. Patient 1 initially received off-label olaparib treatment and achieved partial response, but later experienced disease progression despite multiple treatments. Patient 2 had a partial response to olaparib but developed erythroid hypoplasia and died after disease progression. Patient 3 had stable disease with olaparib but experienced haematotoxicity when carboplatin was added. These case reports highlight the challenges and potential limitations of these treatments for uterine leiomyosarcoma. [Extracted from the article]

A retrospective study involving 33 female patients treated with olaparib for ovarian cancer identified two cases of adverse reactions. In one case, a patient developed pulmonary fibrosis after starting olaparib treatment, which was confirmed by CT scan. The patient's dose of olaparib was subsequently reduced. In another case, a patient experienced elevated glucose levels during olaparib treatment, indicating a prediabetes condition. These findings suggest a potential link between olaparib and the development of prediabetes and pulmonary fibrosis in some patients. [Extracted from the article]

A 67-year-old man with metastatic adenocarcinoma of the prostate experienced lack of efficacy during treatment with docetaxel and prednisolone. He also developed interstitial pneumonia while receiving olaparib for neuroendocrine prostate cancer. The patient had multiple bone and lymph node metastases and underwent various treatments, including radiotherapy and palliative care. Despite a partial response to olaparib, he ultimately died due to neuroendocrine prostate cancer. [Extracted from the article]

A retrospective study was conducted on 126 patients with ovarian cancer who were treated with niraparib or olaparib between January 2017 and October 2020. Two patients developed side effects from the treatment. One patient experienced dysgeusia (a distorted sense of taste) after receiving niraparib, while the other patient developed severe thrombocytopenia (low platelet count) after receiving olaparib. The study did not provide specific details about the patients' ages, genders, dosages, or outcomes. [Extracted from the article]